Pfizer Inc.

Total Valuation

Pfizer Inc. carries a market capitalization of 71.99B, placing it among publicly traded companies globally. Its enterprise value stands at 95.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pfizer Inc. currently has 5.70B shares outstanding.

Valuation Ratios

Pfizer Inc. trades at a trailing price-to-earnings ratio of 29.39. The price-to-sales ratio is 2.00, and the price-to-book ratio stands at 0.51.

Enterprise Valuation

On an enterprise value basis, Pfizer Inc. trades at an EV/EBITDA multiple of 4.03 and an EV/FCF ratio of 5.11. The EV/Sales ratio of 1.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.59 provides insight into valuation relative to core operating earnings.

Financial Position

Pfizer Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 73.92, indicating elevated leverage, while an interest coverage ratio of 8.75 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Pfizer Inc. has paid -164.00M in income taxes, reflecting an effective tax rate of 14.54.

Stock Price Statistics

Pfizer Inc.'s stock has gained approximately 10.59545% over the past 52 weeks. The 50-day moving average sits at 11.95, while the 200-day moving average is 11.83.

Income Statement

Over the trailing twelve months, Pfizer Inc. generated 63.70B in revenue and converted that into 4.33B in net income, yielding earnings per share of 0.26. EBITDA reached 23.60B, while operating income came in at 17.02B.

Balance Sheet

Pfizer Inc. holds 11.70B in cash and equivalents against 63.19B in total debt, resulting in a net debt position of 62.22B. Total book value stands at 85.19B, with working capital of 8.71B providing operational flexibility.

Cash Flow

Pfizer Inc. produced 13.40B in operating cash flow over the past twelve months. After subtracting -2.42B in capital expenditures, free cash flow totaled 10.99B - equivalent to 0.66 per share.

Margins

Pfizer Inc. operates with a gross margin of 73.18, reflecting its pricing power and cost economics. The operating margin of 26.72 and net profit margin of 6.80 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 221.98 indicates the proportion of earnings distributed to shareholders.

Scores

Pfizer Inc. posts an Altman Z-Score of 3.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.